Loading articles...
Cancers driven by tropomyosin 3 (TPM3) gene fusions represent a therapeutic challenge, with resistance mechanisms poorly understood. A comprehensive review highlights the pressing need for improved preclinical models and a deeper understanding of downstream...
Identifying TRK fusion -positive cancers is critical, as targeted therapies offer significant benefits. Oncologists should proactively integrate appropriate testing strategies into their practice to ensure patients receive optimal, personalized treatment.
In colorectal neoplasms care, drug exposure can rarely trigger insulin autoimmune syndrome, where autoantibodies bind insulin and cause unpredictable postprandial hypoglycemia. The key signal is therapy-associated autoimmune hypoglycemia with markedly eleva...
In colorectal neoplasms care, drug-induced insulin autoimmune syndrome can present with recurrent hypoglycemia driven by insulin autoantibodies that bind and later release endogenous insulin. This case highlights the mechanism, diagnostic pathway using insu...
Insulin autoimmune syndrome in colorectal cancer care presents as recurrent hypoglycemia driven by insulin autoantibodies that bind and unpredictably release endogenous insulin. A case from oncology highlights that implicated medications can trigger this me...